Online summary
Correction to: Hale M, et al. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain. Curr Med Res Opin 2010;26:1505-18
Correction to: Hale M, et al. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain. Curr Med Res Opin 2010;26:1505-18
The authors have been made aware of two errors that appeared in their paper.
To be consistent with the text in the body of the paper, where these results were correctly stated, the sentence in the 2nd line of the Abstract Results section on page 1505 should read: “Median diary NRS score change from baseline to endpoint was significantly lower for OROS hydromorphone ER (0.2 units) compared to placebo (1.6 units).”
The first sentence in the Safety Assessment section on page 1515 should read: “Of the 447 patients in the safety population during the conversion/titration phase, 247 (55.3%) patients experienced at least one AE, 6 (1.3%) patients had a serious AE, and 58 (13.0%) patients discontinued from this phase due to an AE.”